The China plus one strategy encourages diversification of suppliers due to geopolitical risks, which benefits Indian companies across various sectors. In pharma, both traditional and CDMO segments show opportunities. The industrial sector grows more attractive as interest rates drop and currency stabilizes. The strategy also provides a competitive edge to Indian exporters facing Chinese competition.
Ahead of Market: 10 things that will decide stock market action on Monday
Indian markets closed lower for the second straight week, dragged by weak earnings, US tariff threats, and global uncertainty. IT stocks underperformed while Glenmark Pharma
July 13, 2025